DK3452039T3 - Behandling af hårtabslidelser med deutererede jakhæmmere - Google Patents

Behandling af hårtabslidelser med deutererede jakhæmmere Download PDF

Info

Publication number
DK3452039T3
DK3452039T3 DK17793380.1T DK17793380T DK3452039T3 DK 3452039 T3 DK3452039 T3 DK 3452039T3 DK 17793380 T DK17793380 T DK 17793380T DK 3452039 T3 DK3452039 T3 DK 3452039T3
Authority
DK
Denmark
Prior art keywords
deuterated
jack
inhibitors
treatment
heart failures
Prior art date
Application number
DK17793380.1T
Other languages
Danish (da)
English (en)
Inventor
Amanda T Wagner
James V Cassella
Philip B Graham
Virginia Braman
Vinita Uttamsingh
Hehn Jana Von
Colleen E Hamilton
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3452039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Application granted granted Critical
Publication of DK3452039T3 publication Critical patent/DK3452039T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17793380.1T 2016-05-04 2017-05-04 Behandling af hårtabslidelser med deutererede jakhæmmere DK3452039T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
DK3452039T3 true DK3452039T3 (da) 2024-10-07

Family

ID=60203616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17793380.1T DK3452039T3 (da) 2016-05-04 2017-05-04 Behandling af hårtabslidelser med deutererede jakhæmmere

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP3452039B1 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR102810262B1 (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022519A1 (en) * 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3129096A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CA3196551A1 (en) * 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CA3250876A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Ind Inc DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
HRP20030873B1 (en) 2001-05-03 2006-04-30 F. Hoffmann - La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CA2876306C (en) * 2012-06-15 2024-02-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
PE20151157A1 (es) 2012-11-15 2015-08-19 Incyte Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CA3022519A1 (en) 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors

Also Published As

Publication number Publication date
PL3452039T3 (pl) 2024-11-18
KR20230086814A (ko) 2023-06-15
CN109069493A (zh) 2018-12-21
US20200222408A1 (en) 2020-07-16
FI3452039T3 (fi) 2024-10-02
BR112018072339A2 (pt) 2019-02-19
AU2025213576A1 (en) 2025-08-21
MX2023002325A (es) 2023-03-22
MX2023002324A (es) 2023-03-22
KR20250070139A (ko) 2025-05-20
AU2017261286B2 (en) 2023-03-23
EP3452039B1 (en) 2024-07-03
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
EP3452039A4 (en) 2019-12-25
RS66006B1 (sr) 2024-10-31
EP4424367A3 (en) 2024-11-13
MX2018013347A (es) 2019-09-02
US20240423986A1 (en) 2024-12-26
KR102810262B1 (ko) 2025-05-19
US10561659B2 (en) 2020-02-18
PT3452039T (pt) 2024-10-07
HRP20241345T1 (hr) 2024-12-20
JP2019516684A (ja) 2019-06-20
MX388054B (es) 2025-03-19
MX2023002321A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
SI3452039T1 (sl) 2024-12-31
JP7586868B2 (ja) 2024-11-19
JP2022171838A (ja) 2022-11-11
JP2025026895A (ja) 2025-02-26
JP7145080B2 (ja) 2022-09-30
MX2023002323A (es) 2023-03-22
SMT202400389T1 (it) 2024-11-15
US12076323B2 (en) 2024-09-03
HUE068643T2 (hu) 2025-01-28
ES2988629T3 (es) 2024-11-21
WO2017192905A1 (en) 2017-11-09
MX2021014175A (es) 2022-01-04
LT3452039T (lt) 2024-10-25
EP3452039A1 (en) 2019-03-13
EP4424367A2 (en) 2024-09-04
US20190160068A1 (en) 2019-05-30
CA3022519A1 (en) 2017-11-09
AU2023201112A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
DK3452039T3 (da) Behandling af hårtabslidelser med deutererede jakhæmmere
DK3198033T3 (da) Anvendelse af mutante fgfr-genpaneler til identificering af kræftpatienter som reagerer på behandling med en fgfr-inhibitor
EP3352757C0 (en) ADMINISTRATION OF DEUTERIUM-MODIFIED CFTR POTENTIATION AGENTS
DK3134530T3 (da) Behandling af hyperbilirubinæmi
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3334709T3 (da) Salte af en lsd1-hæmmer
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
DK3244965T3 (da) Behandling af hovedpine med elektrisk stimulering
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3262046T3 (da) Salte af pi3k-inhibitor og fremgangsmåder til fremstilling deraf
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
DK3139855T3 (da) Scanning af tandløse patienter
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3569166T3 (da) Indretning til akut behandling af hjertestop
IL272851A (en) Methods of using dipivefrin
DK3973959T3 (da) Behandling af kolestatisk kløe med seladelpar
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3307267T3 (da) Behandling af multipel sklerose